News coverage about Celsion (NASDAQ:CLSN) has trended somewhat positive on Sunday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celsion earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.4812816518042 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
Several analysts have recently weighed in on the company. ValuEngine cut Celsion from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Oppenheimer assumed coverage on Celsion in a report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price target on the stock. Finally, Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Celsion has a consensus rating of “Buy” and an average target price of $11.90.
Shares of Celsion (CLSN) traded down $0.06 during mid-day trading on Friday, reaching $2.20. The company had a trading volume of 216,946 shares, compared to its average volume of 339,103. Celsion has a 1-year low of $1.24 and a 1-year high of $6.06. The company has a market capitalization of $35.34, a PE ratio of -0.38 and a beta of 1.81.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/18/celsion-clsn-earning-somewhat-positive-press-coverage-study-shows.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.